Relative to Their Population Size, New England States Should Support Largest Markets for Dyslipidemia Drugs

      Massachusetts, Maine and Vermont Have the Highest Percentages of

Dyslipidemia Patients Who Have Prescription Drug Coverage but Are Currently

    Untreated, According to a New Analytics Tool From Decision Resources



    WALTHAM, Mass., Aug. 14 /EMWNews/ -- Decision Resources, one of the

world's leading research and advisory firms focusing on pharmaceutical and

healthcare issues, finds that, relative to their population size, New

England states theoretically should support some of the largest markets for

dyslipidemia drugs.



    The new analytics tool from Decision Resources entitled PatientFinder:

Dyslipidemia reveals that Massachusetts, Maine and Vermont have the highest

percentage of untreated people with dyslipidemia who also have prescription

(Rx) drug coverage. This potential is currently not being realized due to

low treatment rates in these states. Massachusetts ranks 27th, Maine ranks

36th and Vermont ranks 40th in the percentage of their prevalent population

that are currently receiving drug therapy for dyslipidemia. The result of

this under-treatment is that significant opportunity remains for

dyslipidemia market growth in each of these states. This type of

information is invaluable to pharmaceutical companies who are challenged to

pinpoint the areas of greatest need for their drugs.



    Why Pharmaceutical Companies Need this Information



    With the type of information included in PatientFinder, pharmaceutical

organizations can identify the local markets that offer the greatest

opportunity for their branded drug. Companies can identify markets that are

underserved and determine if they should increase direct-to-consumer

advertising, work with the local managed care organizations to increase

awareness of the disease and benefits of their drug or align sales

representatives to maximize market potential.

    About PatientFinder



    PatientFinder is the only healthcare analytics tool that assesses local

markets for expansion opportunity by determining the number of insured

patients in each territory who have the disease but are untreated.

PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan

statistical areas (MSAs) and provides:



    -- Disease-specific prevalence numbers for each U.S. state and MSA



    -- Examination of treatment rates for the disease population to create

percent treated and percent untreated estimates by state and MSA



    -- Unique analysis of the untreated population examined through a

filter of Rx benefit coverage. The end result is an estimate of how many

patients are untreated but can afford therapy within each territory-the

true local measure of opportunity for pharmaceutical companies



    About Decision Resources



    Decision Resources (http://www.decisionresources.com) is a world leader in

market research publications, advisory services and consulting designed to

help clients shape strategy, allocate resources and master their chosen

markets. Decision Resources is a Decision Resources, Inc. company.








    All company, brand or product names contained in this document may be

       trademarks or registered trademarks of their respective holders.



     For more information, contact:



     Elizabeth Marshall

     Decision Resources

     781-296-2563

     [email protected]